Clear cell renal cell carcinoma (ccRCC) is the most common, aggressive renal malignancy with a poor prognosis and limited advanced therapies.Accumulating evidence highlights the importance of sialylation and sialylation-related long non-coding RNAs (lncRNAs) in tumor progression, immune evasion, and treatment resistance. Thus, this study aimed to develop a prognostic model based on sialylation-related lncRNAs to optimize risk stratification and facilitate personalized treatment for patients with ccRCC.
TCGA-derived ccRCC RNA-seq and clinical data were used to screen differentially expressed sialylation-related lncRNAs (DESRlncRNAs). Cox and LASSO analyses were used to build a 7-lncRNA prognostic signature, whose predictive performance was subsequently validated in both training and testing cohorts. Importantly, we evaluated the independence of this signature and established a novel nomogram to improve prognostic accuracy.
A 7 sialylation-related lncRNA (LINC01943, AC079848.1, UCA1, AC093802.1, AC025580.3, LINC01738, and LINC02073) prognostic signature was successfully established. This signature stratified ccRCC patients into two risk subgroups; patients with high-risk presented worse overall survival. Further analysis revealed the superior predictive accuracy of this model. Functional enrichment indicated activated immune regulatory pathways and elevated PD-1 activity in the high-risk group. Notably, low-risk patients showed higher sensitivity to cisplatin, docetaxel, and paclitaxel, providing a basis for personalized therapeutic strategies.
This study utilized Cox and LASSO regression to construct a prognostic signature comprising seven sialylation-related lncRNAs for ccRCC, which effectively stratified patient prognosis and guided individualized chemoimmunotherapy, offering theoretical support for clinical risk evaluation. However, further experiments are required to validate the biological functions of these seven lncRNAs.
This study identifies a novel 7 sialylation-related lncRNA prognostic signature for ccRCC, which may hold significant implications for guiding personalized treatment and immune modulation in clinical practice.
Current medicinal chemistry. 2026 Jul 10 [Epub ahead of print]
Weiping Huang, Congcong Fan, Yifei Li, Wanyi Shu, Jianjian Zheng, Yeping Li
Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China., Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China., School of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang Province, 325035, China., The First Affiliated Hospital of Wenzhou Medical University Department of Urology Wenzhou China.